The increasing pace of development in molecular biology during the last decade has had a direct effect on mass testing and diagnostic applications, including blood screening. We report the model Microarray that has been developed for Hepatitis B virus (HBV) and Hepatitis D virus (HDV) detection. The specific primer pairs of PCR were designed using the Primer Premier 5.00 program according to the conserved regions of HBV and HDV. PCR fragments were purified and cloned into pMD18-T vectors. The recombinant plasmids were extracted from positive clones and the target gene fragments were sequenced. The DNA microarray was prepared by robotically spotting PCR products onto the surface of glass slides. Sequences were aligned, and the results obtained showed that the products of PCR amplification were the required specific gene fragments of HBV, and HDV. Samples were labeled by Restriction Display PCR (RD-PCR). Gene chip hybridizing signals showed that the specificity and sensitivity required for HBV and HDV detection were satisfied. Using PCR amplified products to construct gene chips for the simultaneous clinical diagnosis of HBV and HDV resulted in a quick, simple, and effective method. We conclude that the DNA microarray assay system might be useful as a diagnostic technique in the clinical laboratory. Further applications of RD-PCR for the sample labeling could speed up microarray multi-virus detection.
Introduction
Viral hepatitis is the most common cause of acute and chronic hepatitis. The term viral hepatitis generally refers to infections resulting from one of the hepatotrophic viruses. Chronic infection by the hepatitis virus affects over 500 million people worldwide (Lok et al., 2001) , is associated with significant morbidity and mortality, and is considered a major public health problem in most areas of the world, which raises issues of its diagnosis, treatment, and prevention (Jay et al., 1997) . Hepatitis B and D viruses are parent rally transmitted, and occur both in the acute and chronic forms. When they persist in a chronic carrier state, they serve as a reservoir for infection and give rise to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). In particular, the laboratory diagnosis of viral hepatitis is important to effectively plan immediate patient management, to determine treatment choices, and to limit the transmission of infection.
In the past decade, improvements in molecular biologybased techniques have yielded highly valuable tools for use in this setting. DNA microarray technology can allow the quantitative and simultaneous analysis of hundreds to thousands of genes (Schena et al., 1995; Schena et al., 1996; Shalon et al., 1996) , and allows the high-throughput screening of multiple pathogens in a large numbers of samples. The DNA chip represents a new category of this developing technology, and is characterized by expedient, large scale, highly automatic, and sensitive detection of biological information regarding DNA and RNA.
In this article, we describe a microarray technology developed for the simultaneous detection of HBV and HDV. The specific PCR primers used were designed using the Primer Premier 5.00 program according to the conserved regions of HBV and HDV. The PCR fragments were purified and cloned into pMD18-T vectors. Recombinant plasmids were extracted from positive clones and the target gene fragments were sequenced. The DNA microarrays were then prepared by robotically spotting PCR products onto the surfaces of glass slides.
Materials and Methods
Probe template The full-length plasmid of HDV pDL553 was *To whom correspondence should be addressed. Tel: 86-20-61648210,36622203; Fax: 86-20-61647755, 36622203 E-mail: wenli@fimmu.edu.cn presented by Dr S. Gudima of the Fox Chase Cancer Center (USA), and the full-length HBV plasmid was constructed in our laboratory.
Chemicals and reagents Premix Taq, dNTP, EcoRI, Sau3AI, pMD18-T vector, and T4 DNA Ligase were obtained from Takara Co. (Shiga, Japan). Plasmid Miniprep kits were purchased from Shen Neng Bo Cai Co. (China), PCR primers of HBV and HDV and the primers in pMD18-T vector were synthesized by BIOASIA Co. (China). The universal primer cy5-GTTTGGCTGGTGTGGATC was purchased from Gibco Co. (Gaithersburg, USA), CMT-GAPS coated glass slides were from Corning Co. (Corning, USA).
Bacterial strains The E. coli strain XL-1 used in these experiments was maintained in our laboratory.
Oligonucleotide primers design Oligonucleotide primers were designed using the Primer Premier 5.00 program and GenBank Blastn sequence alignments. Selected PCR primers met the following criteria: (i) primers hybridized to highly conserved sequence elements, (ii) each amplicon spanned approximately 250-700 bp, (iii) primer melting points generally fell between 50 and 54 o C. We designed 10 and 4 primer pairs respectively according to the conserved region of HBV and HDV. The sequences of the synthetic primers used in the study are shown in Table 1 .
PCR
The plasmids of HBV and HDV (1 µl), respectively, were added to a PCR mixture of total volume 50 µl containing 25 µl 2 × premix, and 2 µl (each) of the oligonucleotide primers (0.25 µM). The mixture was then chilled and the products were sized by 1.5% agarose gel electrophoresis. The PCR products were purified, using a 3S PCR product purification kit V20 (Bocai Corp., Shanghai, China) and stored at −20 o C.
HBV
Identification of the PCR products After purification using the PCR product purification kit, the PCR products were inserted into pMD18-T vector. The ligation mixture which contained 4 µl PCR products, 1 µl pMD18-T vector (50 ng/µl), and 5 µl loading buffer solution was incubated for 4 hours at 16 o C, and then transferred into 100 µl XL-1 E. coli competent cells, which had been previously treated with solutions containing Ca 2+ ions (0.1 M). To transform E. coli, the mixture of DNAs formed in the ligation reaction was combined with a suspension of competent cells for 30 min, then heat-shocked at 42 o C for 1~2 min. The cells were then incubated in a growth medium and finally spread on an agar plate and incubated until single colonies of bacteria grew. Clones containing target fragments were then selected and identified with pMD18-T vector primer (primerA5'-CTAAAACGACGGCC AGT-3', primer B 5'-CAGGA AACAGCTATGAC-3'). The sequence of target fragments were then analyzed using an ABI PRISMTM 377 DNA sequencer, and GenBank Blastn sequence alignments were performed.
Microarray printing and processing
The final concentration of each purified PCR product was adjusted to 0.3 mg/ml with DMSO and water (50% v/v). The DNA microarray was prepared by spotting the PCR products on special glass slides using a Cartesian 5,500 MicroArrayer. The DNAs of the target gene were then crosslinked with ultraviolet irradiation, baked at 80 o C for 2 h, and maintained in closed containers until application. The arrangement of spots on the gene chip is shown in Fig. 1 . After this labeling reaction, the sample DNA fragments of hundreds base pairs were labeled with fluorescent Cy5. The labeled PCR products were then further purified using a 3S PCR product purification kit V20 (Bocai Corp.). 5 µl of the 30 µl purified products was used for hybridization with the microarry probes.
Samples labeling
Prehybridization Microarray slides were placed in a prehybridization solution (5 × SSC, 0.2% SDS, 25% formamide and 1% BSA ) at 42 o C for 1 h, rinsed at room temperature in Milli Q water for 5 times, dehydrated in isopropanol, and air dried.
Hybridization and data analysis 5 µl Cy5 labeled samples were mixed with 1 µl Cot-1 DNA (20 µg/µl, Life Technologies) and 6 µl 2 × hybridization buffer (50% formamide, 10 × SSC, 0.2% SDS), and denatured at 95 o C for 5 mins, centrifuged at 14,000 rpm for HBV probes(10 fragments of genes)
Negative control Empty controls HBV Positive controls HDV Positive controls HDV probes (4 fragments of genes).
2 min, and cooled to room temperature. Three µl of the above mixture was then added to the surface of the microarray, which had been immersed in the prehybridisation medium for 1h, and covered with a glass coverslip pretreated with SIGMACOTE ® (Sigma, St. Louis, USA) to prevent sample evaporation. The slide was placed in a sealed hybridization box; 10 µl UPW was added to every well at the two ends of the chamber. After hybridization at 42 o C for 5 h, the slide was taken out and washed with: 1) low-stringency washing buffer containing 1 × SSC/0.2% SDS at 42 o C for 5 min; 2) highstringency washing buffer containing 0.1 × SSC/0.2% SDS at room temperature for 10 min; 3) 0.1 × SSC for 1 min; 4) Milli Q water; 5) ethanol; respectively. The chip was then desiccated at room temperature. Scanning was performed using a ScanArray Lite Microarray Analysis System (GSI Lumonics Co).
Results

Preparation of HBV and HDV probes for the microarray
From the 1.5% agarose gel electrophoresis results, we found that that all the respective 10 and 4 primer pairs amplified HBV DNA and HDV cDNA and produced products of the expected size (Fig. 2, Fig. 3) .
Confirmation of the DNA obtained from HBV and HDV by sequence analysis By using Blastn and the Genbank database, each sequenced PCR product was confirmed to be a HBV or HDV genome fragment. Fig. 4 and Fig. 5 show one DNA fragment from HBV located at the polymerase gene region and one cDNA fragment from HDV located at the complete genome region, respectively.
Microarray design
The clinical diagnostic microarray was prepared by immobilizing the captured target genes of pathogens on a slide, which was treated specifically. The DNA or RNA extracted from the patient's serum was labeled with fluorochrome and hybridized to the target DNA. In this paper, the microarray was prepared by spotting PCR products of the Analysis of the microarrays hybridized with HBV and HDV DNA by fluorescent scanning From the hybridizing signals obtained using 80% laser energy and 70% GMT on the Gene chip, it was evident that it satisfied the specificity and sensitivity requirements for detecting HBV and HDV, as shown in Fig. 6 . The single array shown in Fig 
Discussion
In China, chronic viral hepatitis is considered a major public health problem. Approximately 150 million individuals have contracted chronic hepatitis B and the incidence rate of HBV infection is 158/1000,00 annually (Jin et al., 2001) . Moreover, up to 40% of these individuals will eventually develop serious hepatic complications. HBV infection can cause acute and chronic liver disease including cirrhosis and HCC. The risk of HCC in individuals that have developed chronic hepatitis B is 300 times higher than in normal people (Jin et al., 2001) . The hepatitis D virus (HDV), a defective virus, requires the supply of hepatitis B surface antigen (HbsAg) envelope by hepatitis B virus (HBV) for its assembly and transmission. During acute and chronic infection, and HDV infection often leads to more severe disease (Porres et al., 1989) .
In the clinical diagnosis of hepatitis virus, antibody-based methods such as ELISA and molecular biologic techniques, such as PCR, and molecular hybridization had been considered practical ways of detecting viral infection. However, such immunoassays suffer from a problem because antibody assays are insufficient for diagnostic purposes due to the brief diagnostic window period and their inability to diagnose patients with hypoimmunity. For viral diagnosis, common nucleic acid hybridization may have a excellent specificity, but sensitivity requirements are not often satisfied. In the protocol of PCR, cross contamination, and the incidents of false negative and false positive often occur, and simply producing DNA provides to indication that the right product has been amplified. DNA microarrays offer a solution to these problems and provide us with a simple and sensitive method of diagnosing hepatitis virus infection. Compared with traditional diagnostic techniques, the technique has a number of obvious advantages-integration, micromation and automatization (Ma et al., 1999) . In principle, one could draw on this resource when needed to clinically diagnose different hepatitis virus subtypes and the strain of drug resistance simultaneously on a microarray slide, and the captured DNA could be assayed in a single reaction. The DNA genechip also offers a dependable basis for clinical laboratory diagnosis, treatment, the monitoring of response to therapy, and the occurrence, development and prognosis of hepatotrophic viral infections (Petrik et al., 2001; Sun et al., 2003a Sun et al., , 2003b .
The chip we developed is cost-effective, and the procedure required to prepare the chip, straightforward and convenient. When results are verified by molecular hybridization, PCR cross contamination can be overcome, and by incorporating negative and positive controls, we detection results are ensured. Subjective factors in terms of judging results were reduced greatly by using analytic software (Falus et al., 1998) . In addition, the sensitivity of the assay may be enhanced by increasing the amount of captured DNA on the slide or by pretreating the sample DNA.
There are two ways of preparing DNA microarray probes: the first one is the PCR amplification of the DNA fragments with a molecular clone, and the other is the artificial synthesis of oligonucleotide arrays using a DNA synthesizing machine. We preferred the first method, making use of Primer Premier 5.00 to design special HBV and HDV primers. While designing the primers, we tried to make the annealing temperatures of HBV and HDV coincide so that the PCR protocol could be performed easily in the same reaction system. Because of the convenience of PCR, we were able to directly prepare DNA microarray probes after purifying the PCR product. As for the small genome of HBV (3.2 Kb) and HDV (1.7 Kb), the method is practical as it offers speedy, and simple clinical application.
Using Restriction Display-PCR RD-PCR Zheng et al., 1998) , Professor MA and ZHENG prepared microarray probes on a massive scale, which were nearly the same length, and developed diagnostic gene chips. Their method for preparing gene chip probes is used in our laboratory at present Mao et al., 2002; . Further applications of this technique for sample labeling could produce good results and speed up muti-virus detection by microarray technology (Feng et al., 2002; Zhang et al., 2002; Li et al., 2003) . By RD amplification of the enzyme digested samples, the sample fragments can be significantly labeled with fluorescent signals, and can produce much stronger hybridizations than conventional labeling methods.
